DOI: 10.36347/sjams.2016.v04i05.062

Pages: 1749-1751

Cutaneous infantile haemangiomas affect approximately 1 in 10 children. They tend to follow a natural course of rapid proliferation during the first year of life and subsequently regress over 5-10 years. Most haemangiomas are nonproblematic, but a few become problematic, through ocular, airway or functional impairment, or ulceration. Until recently, treatment options for problematic haemangioma have included intralesional and systemic steroids, chemotherapeutic agents including vincristine and interferon-alpha, laser therapy or surgical intervention. Oral propranolol therapy has been observed to inhibit the proliferation and incite regression of these lesions during their proliferative phase.